| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | oprI |
| Uniprot No | P11221 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-83aa |
| 氨基酸序列 | MNNVLKFSALALAAVLATGCSSHSKETEARLTATEDAAARAQARADEAYRKADEALGAAQKAQQTADEANERALRMLEKASRK |
| 预测分子量 | 40.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于oprI重组蛋白的3篇代表性文献的简要信息：
---
1. **文献名称**：*"A recombinant OprI fusion protein as a vaccine candidate against Pseudomonas aeruginosa infections"*
**作者**：Mansour, H., et al.
**摘要**：研究构建了oprI与霍乱毒素B亚基的重组融合蛋白，评估其在小鼠模型中诱导的免疫反应，结果显示可显著提高抗体水平并对铜绿假单胞菌感染提供保护。
---
2. **文献名称**：*"Recombinant OprI as a serodiagnostic antigen for Pseudomonas aeruginosa infections"*
**作者**：Lee, J.S., et al.
**摘要**：利用大肠杆菌表达重组oprI蛋白，开发ELISA检测方法，证实其在临床样本中能特异性识别铜绿假单胞菌感染者血清抗体，具有潜在诊断价值。
---
3. **文献名称**：*"Immunoprotective efficacy of OprI-based subunit vaccine against acute pulmonary Pseudomonas aeruginosa challenge"*
**作者**：Smith, R.P., et al.
**摘要**：通过动物实验证明，重组oprI蛋白疫苗可激活Th1/Th2混合免疫应答，显著降低肺部细菌载量并提高感染后生存率，提示其作为预防性疫苗的潜力。
---
注：以上文献信息为示例性质，实际引用时需根据具体论文内容调整。建议通过PubMed或Web of Science以关键词**"recombinant oprI protein"**检索最新文献。
OprI recombinant protein is derived from the outer membrane protein I (OprI) of Gram-negative bacteria, notably *Pseudomonas aeruginosa*, a opportunistic pathogen associated with severe infections in immunocompromised individuals. OprI is a small, highly conserved lipoprotein anchored to the bacterial outer membrane, playing a structural role in membrane stability and serving as a potential virulence factor. Its gene, *oprI*, encodes a protein with a characteristic β-barrel structure, typical of outer membrane proteins, which facilitates interactions with host cells or environmental stressors.
The recombinant form of OprI is produced via genetic engineering, often expressed in *Escherichia coli* systems for scalability and purity. Researchers leverage its immunogenic properties for vaccine development and diagnostic applications. As a vaccine candidate, OprI has shown promise in preclinical studies for inducing protective immune responses against *P. aeruginosa* infections, particularly in models of pneumonia and sepsis. Its conservation across *Pseudomonas* species enhances its appeal as a broad-spectrum antigen.
In diagnostics, OprI serves as a target for antibody detection, aiding in rapid identification of *P. aeruginosa* infections. Its recombinant production ensures standardized antigen quality, reducing cross-reactivity issues common in traditional methods. Additionally, OprI’s role in bacterial membrane dynamics has spurred interest in studying host-pathogen interactions and antimicrobial resistance mechanisms.
Recent advancements include fusion proteins combining OprI with other antigens to enhance immunogenicity and multifunctional nanoparticles for targeted delivery. Despite progress, challenges remain in optimizing stability and efficacy in clinical settings. Overall, OprI recombinant protein represents a versatile tool in combating Gram-negative bacterial infections, bridging gaps between basic research and translational medicine.
×
